Table 2.

HR (with 95% CI) for the specific composite renal outcomes in patients treated with SGLT2is versus placebo according to UACR categories in the cardiovascular RCTs

Trials	Treatment	Composite renal outcomes	UACR categories	HR (95%CI)	P for interaction
EMPA-REG OUTCOME	Empagliflozin	Creat ×2 RRT Death from renal cause	<30 mg/g from 30 to 300 mg/g >300 mg/g	NNA but S NNA but I NNA but S	0.51
CANVAS	Canagliflozin	Creat ×2 ESRD Death from renal cause	<30 mg/g >30 mg/g	0.22 (0.07–0.69) 0.63 (0.38–1.07)	0.09
DECLARE-TIMI 58	Dapagliflozin	−40% ESRD Death from renal cause	<30 mg/g from 30 to 300 mg/g >300 mg/g	0.52 (0.37–0.74) 0.59 (0.39–0.87) 0.38 (0.25–0.58)	0.30
VERTIS CV	Ertugliflozin	Creat ×2 RRT Death from renal cause	<30 mg/g from 30 to 300 mg/g >300 mg/g	0.92 (0.61–1.39) 0.80 (0.53–1.21) 0.62 (0.41–0.95)	0.43

UACR, urinary albumin-to-creatinine ratio; creat x 2,doubling of the serum creatinine; ESRD, end-stage renal disease; NNA but S, numbers not available but significant, meaning that the HR is ˂1 for the treatment and the 95% CI does not cross the zero line; NNA but I, numbers not available but not significant, meaning that the HR is ˂1 for the treatment and the 95% CI does cross the zero line; RRT, renal replacement therapy. 40%, decrease 40% in eGFR.